NCT03086369

A Study of Nab-Paclitaxel and Gemcitabine With or Without Olaratumab (LY3012207) in Participants With Metastatic Pancreatic Cancer

A Phase 1b (Open-Label) / Phase 2 (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine With or Without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 184 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to determine the safety and efficacy of nab-paclitaxel and gemcitabine with or without olaratumab in the treatment of first-line metastatic pancreatic cancer.

Conditions

• Metastatic Pancreatic Cancer

Interventions

Type	Name	Description
DRUG	Olaratumab	Administered IV
DRUG	Nab-paclitaxel	Administered IV
DRUG	Gemcitabine	Administered IV
DRUG	Placebo	Administered IV

Timeline

• Start date: 2017-06-22
• Primary completion: 2021-01-05
• Completion: 2021-06-17
• First posted: 2017-03-22
• Last updated: 2022-06-28
• Results posted: 2022-01-11

Locations

34 sites across 3 countries: United States, Germany, Spain

Regulatory

• FDA-regulated drug study